| scholarly article | Q13442814 |
| P50 | author | Barton Haynes | Q4865631 |
| Georgia D. Tomaras | Q63663866 | ||
| M Anthony Moody | Q73297881 | ||
| Hua-Xin Liao | Q88608388 | ||
| Laurent Verkoczy | Q88773002 | ||
| P2860 | cites work | Few and far between: how HIV may be evading antibody avidity | Q21090507 |
| Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells | Q24646465 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections | Q27488278 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 | Q27662167 | ||
| HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors | Q28302759 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection | Q29619099 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| HIV and autoimmunity | Q33348896 | ||
| Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection | Q33479167 | ||
| Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals | Q33526340 | ||
| Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | Q33591736 | ||
| Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables | Q33614495 | ||
| Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors | Q33725673 | ||
| Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. | Q33781055 | ||
| Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines | Q33794973 | ||
| Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? | Q33887693 | ||
| HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals | Q33943206 | ||
| Duration of humoral immunity to common viral and vaccine antigens | Q45872621 | ||
| Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers | Q48036553 | ||
| Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV. | Q51888603 | ||
| IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. | Q52177381 | ||
| The site and stage of anti-DNA B-cell deletion. | Q52210540 | ||
| Antibodies to lipids and liposomes: immunology and safety. | Q53601276 | ||
| Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. | Q54073056 | ||
| Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression | Q56886558 | ||
| Deletion and editing of B cells that express antibodies to DNA | Q72273763 | ||
| Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals | Q81109508 | ||
| Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques | Q33966586 | ||
| Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop | Q34090517 | ||
| Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness | Q34096475 | ||
| Immunologic and virologic events in early HIV infection predict subsequent rate of progression | Q34127870 | ||
| Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine | Q34157802 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles | Q34406977 | ||
| Specificity of the autologous neutralizing antibody response | Q34415389 | ||
| B cells in HIV infection and disease | Q34605780 | ||
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia | Q34848486 | ||
| HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection | Q34952914 | ||
| Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 | ||
| Is developing an HIV-1 vaccine possible? | Q35043547 | ||
| Autoreactivity in human IgG+ memory B cells | Q35729131 | ||
| Control of HIV-1 infection by soluble factors of the immune response | Q35752416 | ||
| Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development | Q36041356 | ||
| Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection | Q36225040 | ||
| HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy | Q36401419 | ||
| Antibody polyspecificity and neutralization of HIV-1: a hypothesis | Q36487151 | ||
| A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120 | Q36748055 | ||
| Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation | Q36977531 | ||
| Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. | Q37347813 | ||
| Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression | Q37356036 | ||
| HIV infection of the genital mucosa in women. | Q37370910 | ||
| Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region | Q37410792 | ||
| Role of HIV membrane in neutralization by two broadly neutralizing antibodies | Q37453499 | ||
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? | Q37519312 | ||
| Follicular dendritic cells in HIV-induced lymphadenopathy and AIDS. | Q38648230 | ||
| Persistent immune activation in HIV-1 infection is associated with progression to AIDS. | Q39060564 | ||
| The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain | Q40130304 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines | Q40546496 | ||
| Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers | Q40659603 | ||
| Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design | Q41338220 | ||
| Broadly Reactive Antibody-Dependent Cellular Cytotoxic Response to HIV-1 Envelope Glycoproteins Precedes Broad Neutralizing Response in Human Infection | Q41706173 | ||
| Regulation of anti-phosphatidylserine antibodies | Q44321091 | ||
| Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection | Q45408309 | ||
| Human immunodeficiency virus infection and systemic lupus erythematosus | Q45654140 | ||
| Monoclonal antibodies to human immunodeficiency virus: their relation to the patterns of lymph node changes in persistent generalized lymphadenopathy and AIDS. | Q45833842 | ||
| Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus | Q45836321 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 108-116 | |
| P577 | publication date | 2010-11-26 | |
| P1433 | published in | Trends in Molecular Medicine | Q15265842 |
| P1476 | title | B cell responses to HIV-1 infection and vaccination: pathways to preventing infection | |
| P478 | volume | 17 |
| Q36807838 | Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes |
| Q36760169 | Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1 |
| Q36202092 | Antiretroviral naive and treated patients: Discrepancies of B cell subsets during the natural course of human immunodeficiency virus type 1 infection |
| Q34273373 | B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study |
| Q44257610 | Biomarkers of natural and vaccine immunity against HIV. |
| Q36079024 | Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising |
| Q35640984 | DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers |
| Q36088254 | Discrete partitioning of HIV-1 Env forms revealed by viral capture. |
| Q34594036 | Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. |
| Q35192726 | Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen |
| Q38059499 | Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells |
| Q38827936 | Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells |
| Q45355729 | Epstein-Barr virus genome load is increased by therapeutic vaccination in HIV-l carriers, and further enhanced in patients with a history of symptomatic primary infection |
| Q34819651 | Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic |
| Q27022055 | HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design |
| Q33577972 | HIV-1 vaccines: challenges and new perspectives |
| Q45360438 | Host-Epstein-Barr virus relationship affected by immunostimulation in HIV-infected patients representing distinct progressor profile groups |
| Q30234773 | Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem |
| Q34177732 | Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies |
| Q37096865 | Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques |
| Q42278743 | Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses |
| Q34280115 | Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum |
| Q38131901 | Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses |
| Q38097613 | On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development? |
| Q34992787 | Polyreactivity and autoreactivity among HIV-1 antibodies |
| Q35336374 | Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls |
| Q35058698 | Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women |
| Q42276031 | SIV antigen-specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL-12. |
| Q36795861 | Short communication: antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire |
| Q37409232 | The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression |
| Q33772637 | Which Antibody Functions are Important for an HIV Vaccine? |
Search more.